Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8465-8471

  Soumaoro, Labile Togba ^a   Uetake, Hiroyuki ^a   Higuchi, Tetsuro ^a   Takagi, Yoko ^a   Enomoto, Masayuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; COHORT STUDIES; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECTAL NEOPLASMS; RECTUM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 11144224065     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0653     Document Type: Article

References (52)

1. Ricchi P, Zarrilli R, di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003;88:803-7.
2. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst (Bethesda) 2001;93:583-96.
3. Kotake K, Honjo S, Sugihara K, et al. Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 2003;46(Suppl):S32-43.
4. Ratio C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer: literature review for clinical application. Dis Colon Rectum 1998;41:1033-49.
5. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
6. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
7. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxidase synthase 2. Cell 1995;83:493-501.
8. 716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2). Cell 1996;87:803-9.
9. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
10. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Investig 1997;100:1325-9.
11. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
12. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. J Am Med Assoc 1999;282:1254-7.
13. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545-53.
14. Masunaga R, Kohno H, Dhar KD, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-8.
15. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47.
16. Kojima M, Morisaki T, Uchiyama A, et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 2001;8:458-65.
17. Yamauchi T, Watanabe M, Kubota T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98-103.
18. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-41.
19. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
20. 716 Mouse intestinal polyps. Cancer Res 2002;62:506-11.
21. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
22. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of Rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-60.
23. Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. Cox-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002;22:1225-30.
24. Hermanek P, Sobin LH. UICC/TNM classification of malignant tumors. 4th ed. New York: Springer-Verlag; 1987. p. 47-9.
25. Fujita T, Matsui M, Takaku K, et al. Size-and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6.
26. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer (Phila.) 2001;15:1876-81.
27. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8.
28. Buecher B, Heymann MF, Lievre A, et al. Cyclooxygenase-2 overexpression in sporadic colorectal carcinoma without lymph node involvement. Aliment Pharmacol Ther 2003;18:731-40.
29. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003;9:1421-6.
30. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-7.
31. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (Phila.) 2003;97:2978-87.
32. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
33. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
34. Erkinheimo TL, Lassus H, Finne P, et al. Elevated cyclooxygenase-2 is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004;10:538-45.
35. Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of Cox-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003;9:1990-4.
36. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31:147-54.
37. Hull MA, Fenwick SW, Chappie KS, Scott N, Toogood GJ, Lodge P. Cyclooxygenase-2 expression in colorectal liver metastases. Clin Exp Metastasis 2000;18:21-7.
38. van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171-9.
39. Cao Y, Prescott SM. Many actions of Cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-86.
40. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9:1741-9.
41. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-11.
42. Hase T, Yoshimura R, Matsuyama M, et al. Cyclooxygenase-1 and -2 in human testicular tumors. Eur J Cancer 2003;39:2043-9.
43. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min Mice. Cancer Res 2000;60:4705-8.
44. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
45. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst (Bethesda) 1991;83:355-8.
46. Sandler RS, Halabi S, Baron JA, et al. A Randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
47. Takeda H, Sonoshita M, Oshima H, et al. Cooperation of cyclooxygenase-1 and cyclooxygenase-2 in intestinal polyposis. Cancer Res 2003;63:4872-7.
48. Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92.
49. Milella M, Gelibter A, Cosimo SD, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-8.
50. Liao Z, Milas L, Komaki R, Stevens C, Cox JD. Combination of a Cox-2 inhibitor with radiotherapy or radiochemotnerapy in the treatment of thoracic cancer. Am J Oncol 2003;26(4 Suppl 2):S85-91.
51. Fenwick SW, Toogood GJ, Lodge JPA, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 2003;125:716-29.
52. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 2003;105:868-72.